nach oben

International Journal of Hematology

Erschienen in:

01.04.2014 | Original Article

Two middle-age-onset hemochromatosis patients with heterozygous mutations in the hemojuvelin gene in a Chinese family

verfasst von: Shufeng Li, Jun Xue, Baojun Chen, Qiwei Wang, Minke Shi, Xiaojing Xie, Liang Zhang

Erschienen in: International Journal of Hematology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Hereditary hemochromatosis is a disorder characterized by enhanced intestinal absorption of dietary iron. Here, we report a heterozygous genotype at two mutation sites in hemojuvelin (HJV) present in two brothers with middle-age-onset hemochromatosis in a Chinese family. To date, only homozygous or compound heterozygous states of HJV gene have been reported as associated with iron overload. However, the patients here were heterozygous for two mutations in one HJV allele in cis: a premature termination mutation (962G>A and 963C>A; C321X) and a mutation in the signal peptide (18G>C; Q6H). Previously unrecognized environmental or other genetic factors may have interacted with the heterozygous genotype in these patients.

Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. Am J Hematol. 2006;81:202–9.PubMedCrossRef

Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dubé MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis. Nat Genet. 2004;36:77–82.PubMedCrossRef

Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood. 2004;103:4669–71.PubMedCrossRef

Lanzara C, Roetto A, Daraio F, Rivard S, Ficarella R, Simard H, et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood. 2004;103:4317–21.PubMedCrossRef

Gehrke SG, Pietrangelo A, Kascák M, Braner A, Eisold M, Kulaksiz H, et al. HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet. 2005;67:425–8.PubMedCrossRef

Barton JC, Sawada-Hirai R, Rothenberg BE, Acton RT. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis. 1999;25:147–55.PubMedCrossRef

Lee PL, Halloran C, West C, Beutler E. Mutation analysis of the transferrin receptor-2 gene in patients with iron overload. Blood Cells Mol Dis. 2001;27:285–9.PubMedCrossRef

Majore S, Binni F, Pennese A, De Santis A, Crisi A, Grammatico P. HAMP gene mutation c.208T>C (p. C70R) identified in an Italian patient with severe hereditary hemochromatosis. Hum Mutat. 2004;23:400.PubMedCrossRef

Koyama C, Wakusawa S, Hayashi H, Ueno T, Suzuki R, Yano M, et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med. 2005;44:990–3.PubMedCrossRef

10.

Brasse-Lagnel C, Poli M, Lesueur C, Grandchamp B, Lavoinne A, Beaumont C, et al. Immunoassay for human serum hemojuvelin. Haematologica. 2010;95:2031–7.PubMedCentralPubMedCrossRef

11.

Kuninger D, Kuns-Hashimoto R, Nili M, Rotwein P. Pro-protein convertases control the maturation and processing of the iron-regulatory protein, RGMc/hemojuvelin. BMC Biochem. 2008;9:9.PubMedCentralPubMedCrossRef

12.

Maxson JE, Chen J, Enns CA, Zhang AS. Matriptase-2- and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression. J Biol Chem. 2010;285:39021–8.PubMedCentralPubMedCrossRef

13.

Lin L, Nemeth E, Goodnough JB, Thapa DR, Gabayan V, Ganz T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis. 2008;40:122–31.PubMedCentralPubMedCrossRef

14.

Silvestri L, Pagani A, Fazi C, Gerardi G, Levi S, Arosio P, et al. Defective targeting of hemojuvelin to plasma membrane is a common pathogenetic mechanism in juvenile hemochromatosis. Blood. 2007;109:4503–10.PubMedCrossRef

15.

De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G, et al. Natural history of juvenile haemochromatosis. Br J Haematol. 2002;117:973–9.PubMedCrossRef

16.

Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 2008;111:5195–204.PubMedCentralPubMedCrossRef

17.

Lin A, Yan WH, Xu HH, Zhu M, Zhou MY. Analysis of the HFE gene (C282Y, H63D and S65C) mutations in a general Chinese Han population. Tissue Antigens. 2007;70:252–5.PubMedCrossRef

18.

Kng C, Ng FH, Ng WF, Wong BC, Grosso LE, Brunt EM, et al. A Chinese patient with non-HFE-linked iron overload. J Clin Gastroenterol. 2001;33:69–71.PubMedCrossRef

19.

Koyama C, Hayashi H, Wakusawa S, Ueno T, Yano M, Katano Y, et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol. 2005;43:740–2.PubMedCrossRef

20.

Aguilar-Martinez P, Lok CY, Cunat S, Cadet E, Robson K, Rochette J. Juvenile hemochromatosis caused by a novel combination of hemojuvelin G320V/R176C mutations in a 5-year old girl. Haematologica. 2007;92:421–2.PubMedCrossRef

21.

Janosi A, Andrikovics H, Vas K, Bors A, Hubay M, Sápi Z, et al. Homozygosity for a novel nonsense mutation (G66X) of the HJV gene causes severe juvenile hemochromatosis with fatal cardiomyopathy. Blood. 2005;105:432.PubMedCrossRef

22.

Daraio F, Ryan E, Gleeson F, Roetto A, Crowe J, Camaschella C. Juvenile hemochromatosis due to G320V/Q116X compound heterozygosity of hemojuvelin in an Irish patient. Blood Cells Mol Dis. 2005;35:174–6.PubMedCrossRef

23.

Huang FW, Rubio-Aliaga I, Kushner JP, Andrews NC, Fleming MD. Identification of a novel mutation (C321X) in HJV. Blood. 2004;104:2176–7.PubMedCrossRef

24.

Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117:1933–9.PubMedCentralPubMedCrossRef

Titel: Two middle-age-onset hemochromatosis patients with heterozygous mutations in the hemojuvelin gene in a Chinese family
verfasst von: Shufeng Li
Jun Xue
Baojun Chen
Qiwei Wang
Minke Shi
Xiaojing Xie
Liang Zhang
Publikationsdatum: 01.04.2014
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 4/2014
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-014-1547-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Two middle-age-onset hemochromatosis patients with heterozygous mutations in the hemojuvelin gene in a Chinese family

Abstract

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients

Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function

Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center

Progress towards gene therapy for haemophilia B

Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission

Concurrent presentation of nodal myeloid sarcoma and bone marrow chronic lymphocytic leukemia/small lymphocytic lymphoma: a unique association

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie